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Abstract
In chronic myeloid leukemia (CML), early treatment prediction is important to identify
patients with inferior overall outcomes. We examined the feasibility of using reductions in
BCR-ABL1 transcript levels after 1 month of tyrosine kinase inhibitor (TKI) treatment to pre-
dict therapy response. Fifty-two first-line TKI-treated CML patients were included (imatinib
n = 26, dasatinib n = 21, nilotinib n = 5), and BCR-ABL1 transcript levels were measured at
diagnosis (dg) and 1, 3, 6, 12, 18, 24, and 36 months. The fold change of the BCR-ABL1
transcripts at 1 month compared to initial BCR-ABL1 transcript levels was used to indicate
early therapy response. In our cohort, 21% of patients had no decrease in BCR-ABL1 tran-
script levels after 1 month and were classified as poor responders. Surprisingly, these
patients had lower BCR-ABL1 transcript levels at dg compared to responders (31% vs.
48%, p = 0.0083). Poor responders also significantly more often had enlarged spleen (55%
vs. 15%; p<0.01) and a higher percentage of Ph+ CD34+CD38- cells in the bone marrow
(91% vs. 75%, p<0.05). The major molecular response rates were inferior in the poor
responders (at 12m 18% vs. 64%, p<0.01; 18m 27% vs. 75%, p<0.01; 24m 55% vs. 87%,
p<0.01). In conclusion, early treatment response analysis defines a biologically distinct
patient subgroup with inferior long-term outcomes.
Introduction
Chronic myeloid leukemia (CML) is caused by the Philadelphia chromosome (Ph), which
induces the formation of the BCR-ABL1 fusion protein. It has constant tyrosine kinase activity
leading to uncontrolled cell proliferation.[1–3] Tyrosine kinase inhibitors (TKIs) blocking the
PLOS ONE | DOI:10.1371/journal.pone.0171041 January 30, 2017 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: El Missiry M, Hjorth-Hansen H, Richter J,
Olson-Stro¨mberg U, Stenke L, Porkka K, et al.
(2017) Early BCR-ABL1 Transcript Decline after 1
Month of Tyrosine Kinase Inhibitor Therapy as an
Indicator for Treatment Response in Chronic
Myeloid Leukemia. PLoS ONE 12(1): e0171041.
doi:10.1371/journal.pone.0171041
Editor: Persio Dello Sbarba, Universita degli Studi
di Firenze, ITALY
Received: November 5, 2016
Accepted: January 13, 2017
Published: January 30, 2017
Copyright: © 2017 El Missiry et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This work was supported by the
Academy of Finland (SM, http://www.aka.fi/en/);
the Finnish Cancer Societies (SM, https://www.
cancersociety.fi/); Sigrid Juselius Foundation (AK,
SM, http://www.sigridjuselius.fi/foundation);
Finnish Cancer Institute (SM); Signe and Ane
Gyllenberg Foundation (SM, http://gyllenbergs.fi/
BCR-ABL1 oncokinase activity have revolutionized the treatment and prognosis of CML. The
first-generation TKI imatinib has been followed by the second-generation inhibitors dasatinib
and nilotinib, which induce faster and deeper molecular responses.[4–6] The current treat-
ment goal of TKI therapy is to achieve first a major molecular response (MMR; BCR-ABL1
transcripts<0.1% in the International Scale) and later deeper molecular responses, such as
MR4.0 and MR4.5. According to the 2013 European Leukemia Net (ELN) recommendations,
MMR is expected to be reached by 12 months,[7] as it has been shown that patients who have
achieved this treatment goal have significantly better overall survival.[4,7–9] The 12-month
MMR rates for nilotinib and dasatinib have been reported to be between 45% and 81%,
whereas with imatinib the MMR rates are generally lower.[10,11]
Even though the majority of CML patients achieve very good therapy responses, a small
fraction of patients does not respond to the assigned TKI. Therefore, early prediction of the
treatment response remains one of the major focuses for researchers as well as clinicians, in
order to find the ideal time to increase the dose or switch the type of TKI to achieve optimal
long-term outcome and avoid relapse. Several methods to predict treatment responses have
been established either by using diagnostic scores (Sokal, Euro, or EUTOS scores) or by assess-
ing the level of leukemic cell burden via cytogenetics or molecular genetics during treatment.
[7,12–14] These days, the BCR-ABL1 mRNA molecular assessments are the most accurate and
common way to evaluate response. Recently, it has been shown that the evaluation of early
treatment response at 3 months may be of importance.[15–18] Several studies have indicated
that patients with a BCR-ABL1 transcript level lower than 10% at 3 months have an overall sur-
vival rate of 95% in comparison with 85% in patients above this level.[7,15,16,19]
As the treatment responses to TKIs are generally very fast, we hypothesized that the predic-
tion of overall treatment response could be done earlier than 3 months, particularly with the
emergence of newer TKI compounds. Therefore, in this study, we have analyzed the initial
decline of BCR-ABL1 transcript levels during the first month of therapy and its importance for
later achievement of optimal treatment responses.
Patients and Methods
Study patients
A total of 52 newly diagnosed chronic phase CML patients from the Nordic countries (Fin-
land, Sweden, and Norway) were included in this study. Of them, 26 patients started on imati-
nib, 21 on dasatinib, and 5 on nilotinib as first-line therapy. The patients had participated in
either the NordCML006 (NCT00852566) or the ENESTnd (NCT00471497) clinical trials,
[11,20] and the only selection criterion was that both diagnostic phase and 1-month PCR val-
ues should be available for analysis. Patients provided written informed consent before the
start of the trial. The study was approved by the Helsinki University Central Hospital ethics
committee with the consideration of the principles of the Helsinki Declaration.
Molecular and cytogenetic response analysis
Molecular genetic analysis was performed with real-time quantitative PCR (RQ-PCR) analyses
to detect the amount of BCR-ABL1 transcripts in the peripheral blood cells by TaqMan1
chemistry. RT reaction conditions and RQ-PCR assays were performed according to the pro-
tocol of the Europe Against Cancer (EAC) Program [21], using either ABL or GUS as reference
genes. The same reference gene was used in all individual patients throughout the follow-up.
The BCR-ABL1 transcript values were reported in the international scale (BCR-ABLIS).[22]
Molecular treatment responses were evaluated at diagnosis (dg) and 1, 3, 6, 12, 18, 24, and 36
months after the start of TKI treatment. Karyotyping of bone marrow (BM) cells was performed
Early BCR-ABL1 Transcript Decline in CML
PLOS ONE | DOI:10.1371/journal.pone.0171041 January 30, 2017 2 / 17
en/); Otto A. Malm Foundation (MEM, http://en.
ottomalm.fi.kotisivukone.com). The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the
manuscript.
Competing Interests: SM and KP have received
honoraria and research funding from Novartis,
Bristol-Myers Squibb, and Pfizer. SM has received
research funding from Ariad. HHH has received
honoraria from Novartis, Bristol-Myers Squibb and
Ariad. JR has received honoraria and research
funding from Novartis and Bristol-Myers Squibb.
NCMLSG has received research funding from
Bristol-Myers Squibb for the NordCML006 study.
This does not alter our adherence to PLOS ONE
policies on sharing data and materials.
using standard G-banding analysis of at least 20 metaphases at dg and 1, 3, and 6 months after
therapy started.
Cell sorting and fluorescence in situ hybridization (FISH)
Mononuclear cells from BM samples were separated using Ficoll centrifugation (GE Health-
care Bio-Sciences AB, Uppsala, Sweden). CD34 positive (CD34+) cells were further enriched
using paramagnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany), and they were
stained after separation with fluorescence-conjugated CD34 and CD38 antibodies (BD Biosci-
ences, San Jose, CA, USA). CD34+ cells were sorted with FACS Aria flow cytometry (BD
Biosciences) into CD38- and CD38+ fractions. Leukemic Ph+ cells in the two separated popu-
lations were determined using the FISH technique with a dual-fusion dual-color BCR-ABL1
probe (Vysis, Abbot, Downers Grove, IL, USA). [20,23] At least 1000 cells were counted from
each cell fraction.
Clinical data
At dg, patients were subjected to full clinical examination, including spleen size assessment by
palpation. The CML risk status was evaluated according to the Sokal and Euro scoring sys-
tems.[7,13,14] Laboratory assessments both at dg and during follow-up included complete
blood counts comprising white blood cell (WBC) counts and differential counts, red blood cell
(RBC) counts, hemoglobin, hematocrit and red blood cell indices and platelet counts. In addi-
tion, BM morphology analysis and karyotyping were performed at dg and during follow-up.
Statistical analysis
GraphPad Prism 6.0 and SPSS 22 were used for statistical analysis. Unpaired t-tests, chi-square
tests, and one-way ANOVAs were applied when appropriate. P-values<0.05 were considered
significant.
Results
Twenty-one percent of patients had no decline in BCR-ABL1 transcript
levels during the first month of TKI therapy
Patients were first divided into two groups based on the decline of BCR-ABL1 transcripts at 1
month compared to diagnostic values. Patients with a fold change (FC) higher than 1 (i.e., no
decrease in BCR-ABL1 transcript values during the first month [FC>1]) were classified as poor
responders (n = 11, 21% of total) and those lower than 1 (FC<1) as responders (n = 41). The
median FC for the responders was 0.31, and this group of patients was further divided into
intermediate responders (0.31<FC<1) and good responders (FC<0.31) (Fig 1A). In most of the
poor responders, the BCR-ABL1 transcript levels markedly increased during the first month of
therapy when compared to the basal level at dg (Fig 1A).
Poor responders had lower BCR-ABL1 transcript levels at diagnosis (dg)
We next investigated factors possibly associated with increased disease burden at 1 month.
Importantly, all patients were using the drug continuously, and no discontinuations or dose
reductions were reported during the first month. First, we compared the initial BCR-ABL1
transcript levels at dg between the poor responder and responder groups. Surprisingly, the
BCR-ABL1 transcript level in the poor responder group (median 30.5, range 10.9–47.2) was
significantly lower than in the responder group (median 47.8, range 12.9–156.5) (p<0.01)
(Fig 1B).
Early BCR-ABL1 Transcript Decline in CML
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As the use of different reference genes (GUS and ABL) may impact the BCR-ABL1 transcript
level at dg,[22] we divided the patients into two groups based on the reference gene used. We
observed that the cases analyzed with the ABL gene had a significantly higher BCR-ABL1 tran-
script level than the patients analyzed with GUS (BCR-ABL1/ABLmedian level 54.5% [range
17.5–156.6] vs. BCR-ABL1/GUSmedian level 34.8% [range 10.9–124.6] (p<0.05). As GUS was
the reference gene in the majority of cases (n = 33), we also compared the diagnostic phase
BCR-ABL1 transcript levels between poor responders and responders in GUS control gene
patients. Interestingly, we observed that the difference between the two groups remained sig-
nificant, and poor responders had lower initial BCR-ABL1 transcript values (median 30.5%,
range 10.9–47.2) compared to responders (median 43.6%, range 12.9–124.6) (p<0.05) (S1 Fig).
Fig 1. A proportion of CML patients do not respond during the first month of TKI therapy. A) The
1-month BCR-ABL1 transcript value was divided by the BCR-ABL1 transcript value at dg, and poor
responders were identified as patients with fold change (FC) >1 (no decrease in the BCR-ABL1 transcript
level after 1 month). The patients with an FC lower than 1 were defined as responders. Furthermore, we used
the median FC (0.31) of the responders to divide these patients into an intermediate responders group
(0.31<FC<1) and good responders group (FC<0.31). B) The initial BCR-ABL1 transcript level at dg was
significantly lower for the poor responders than for the responders (p<0.01). Statistical significance was
analyzed with an unpaired two-tailed t-test, and median values are noted with lines.
doi:10.1371/journal.pone.0171041.g001
Early BCR-ABL1 Transcript Decline in CML
PLOS ONE | DOI:10.1371/journal.pone.0171041 January 30, 2017 4 / 17
In the following paragraphs, we report the data from the whole patient cohort, including
patients with either the GUS and ABL control genes. However, patients with the GUS control
gene were also analyzed separately and showed similar results, and these are reported in the
S1–S7 Figs. Supplemental figures showing only patients with the GUS control gene are enu-
merated identically to the corresponding main figures (i.e. S2A Fig corresponds Fig 2A). It
should be noted that in each individual patient, only one control gene (either GUS or ABL)
was used during the diagnostic and follow-up molecular analysis.
Poor responders had a higher Ph+CD34+CD38- burden, an enlarged
spleen, and a lower hemoglobin level at the time of dg
When we analyzed Ph positive (Ph+) putative leukemic stem cells (Ph+ CD34+CD38-) in the
BM at dg, we found that the proportion out of all CD34+CD38- cells was significantly higher
in poor responders (median 91.3%, range 73.4–100) than in responders (median 75.3%, range
0.6–98.5) (p<0.05) (Fig 2A and S2A Fig for the GUS-only result). The percentage of Ph+
CD34+CD38+ progenitor cells did not differ between the two groups (99.0 vs. 94.9%, p>0.05)
(Fig 2B and S2B Fig).
Further analysis of clinical variables at dg revealed that the spleen was more frequently
enlarged in the poor responders (6/11; 54.5%, median size 5 cm below costal margin) compared
to the responders (6/41; 14.5%, median 0 cm below the costal margin) (t-test p<0.05; chi-
square test p<0.01) (Fig 2C and 2D and S2C and S2D Fig). Moreover, hemoglobin levels were
significantly lower in the poor responders (median 105g/L, range 88–122g/L) than in the
responders (128g/L, range 82–154g/L) (p<0.001) (Fig 2E and S2E Fig).
Blasts, basophils, and total leukocyte and lymphocyte counts showed no difference between
the two groups either at dg or during follow-up (3, 6, 12, and 18 months). Similarly, other fac-
tors, such as the type of TKI used, age, sex, and Euro or Hasford scores, were equal between
the two groups (S1 and S2 Tables). All 11 poor responders were treated with hydroxyurea prior
to TKIs, whereas only 17/41 (41.5%) of the responders had been treated with hydroxyurea
(pchi square<0.01).
Slower eradication of Ph+CD34+CD38- and Ph+CD34+CD38+ cells in
the poor responders
One month after the start of treatment, the BCR-ABL1 transcript level was notably increased in
poor responders (median at dg 30.5%, and 40.2% at 1m; p = 0.04), while the responders had a
marked decrease in the BCR-ABL1 transcript level (median at dg 47.8%, and 13.9% at 1m;
p<0.0001). As a result, the BCR-ABL1 transcript level at 1 month was significantly higher in
poor responders (median 40.2%, range 11–98.7), when compared to the responders (median
13.9%, range 0.9–106.6, p<0.01) (Fig 3A and S3A Fig). The 3- and 6-month time points fol-
lowed the same trend (median BCR-ABL1 transcript levels for 3 months were 4.7% and 0.7%
for poor responders and responders, respectively; while levels for 6 months were 1.2% and
0.15% for poor responders and responders, respectively).
Consistent with the changes in BCR-ABL1 transcript levels, the Ph+CD34+CD38- cell bur-
den showed a dramatic decrease for responders after 1 month (median at dg 75.3%, and 11.1%
at 1m; p<0.0001) (Fig 3B and S3B Fig) while a more modest decrease was observed in the poor
responders (median at dg 91.3%, and 56.2% at 1m; p<0.05, Fig 3B). Accordingly, the percent-
age of Ph+ CD34+CD38- in poor responders was higher than in responders at 1 and 3 months
(1m, median 56.2% [range 1.1–97] vs. 11.1% [range 0–98], p = 0.11; 3m, median 2.8% [range
0–34.86] vs. 0.2% [range 0–7.8] p<0.01) (Fig 3B and 3C, Fig 4A and 4B, S3B and S3C Fig, S4A
and S4B Fig). No significant differences were observed at 6 months.
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Fig 2. The poor responders have a higher percentage of Ph+CD34+CD38- cells and an enlarged spleen at diagnosis (dg). The proportion of Ph+ cells
in the CD34+CD38- and CD34+CD38+ cell compartments was analyzed by sorting and FISH. A) The poor responders had a higher proportion of Ph+CD34
+CD38- cells at dg when compared to the responder group (p<0.05). B) The proportion of Ph+CD34+CD38+ cells at dg. C) Difference in the size of the spleen
(measured as the palpable part under the costal margin) between the poor responder and responder groups (p<0.05). D) Proportion of patients with enlarged
spleen (pchi square <0.01). E) Hemoglobin levels in poor responders and responders. Statistical significance was analyzed with an unpaired two-tailed t-test,
and median values are noted with lines. In panel D, the chi-square test was used.
doi:10.1371/journal.pone.0171041.g002
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Fig 3. The Ph+CD34+CD38- cells are eradicated more slowly in poor responders. A) At 1 month, the BCR-ABL1 transcript level was
significantly higher in poor responders (median 40.2%, range 11–98.7) compared to responders (median 13.9%, range 0.9–106.6) (p<0.01) B) At
Early BCR-ABL1 Transcript Decline in CML
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Similarly, the Ph+CD34+CD38+ cells decreased rapidly in the responder group (median at
dg 94.7%, and at 1m 32.0%, p<0.0001) (Fig 4C). Notably, the poor responders still had a high
Ph+CD34+CD38+ cell pool at 1 month (median at dg 99%, and at 1m 86.5%; p<0.05) (Fig
3D). Accordingly, the percentage of Ph+CD34+CD38+ cells was significantly higher at 1
month in the poor responders than in the responders (1m, median 86.5% [range 34.2–94.8] vs.
31.9% [0.9–98.6], p<0.01 (Figs 3D, 4C and 4D and S3D, S4C and S4D Figs). No significant dif-
ference was observed at 6 months.
All responders had <10% BCR-ABL1 transcript levels at 3 months
despite having high initial BCR-ABL1 transcript levels
We also compared our classification based on the FC to the 3-month response classification
suggested in several studies (BCR-ABL1 transcripts>10% as a sign of poor response).
[7,15,16,19] We observed that all good responders (n = 17) had BCR-ABL1 transcripts<10% at
3 months, whereas 24% (5/21 cases) of the intermediate group and 36% (4/11 cases) of the poor
responder group had a BCR-ABL1 transcript level higher than 10% at 3 months (p<0.01; Fig 5
and S5 Fig, patient subgroups are shown in Fig 1A and S1A Fig).
Poor responders had lower MMR rates at 12 and 18 months compared
to responders
When later treatment responses were considered, we observed that the poor responder group
had a significantly lower proportion of patients who achieved MMR at 12 months (only 2/11
[18%] of cases compared to 25/39 [64%] of cases in the responders; p<0.01, Fig 6A and S6A
Fig). Furthermore, at 18 months, only 3/11 (27%) of the poor responders achieved MMR
compared to 27/36 (75%) of the responders (p<0.01) (Fig 6B and S6B Fig). In addition, the
BCR-ABL1 transcript values at 12 months were higher for the poor responders when compared
to the responders (0.5% vs. 0.03%; p<0.05) (Fig 6C and S6C Fig), and at 18 months, the value
was 0.2% vs. 0.02% (p = ns) (Fig 6D and S6D Fig), respectively. Furthermore, according to
the ELN 12-month classification[7] only 2 of the 11 poor responders (18%) achieved optimal
response, while 6/11 cases were classified as warning (54%) and 3/11 cases as failures (27%). In
contrast, in the responders (n = 41), 26 achieved optimal response (65%), 9 (22.5%) were cate-
gorized as warning, and 5 (12.5%) failed (p<0.0) (Fig 6E and S6E Fig).
When the responders were further divided into good responders (FC<0.31) and intermediate
responders (0.31<FC<1) based on the median FC value of all responders (Fig 1A), we found
that the good responders had the highest MMR rate at 12 months (15/20 cases; 75%) as well as
at 18 months (15/18 cases; 83%). In addition, the intermediate group showed higher response
rates (at 12 months, 10/19 cases [53%] reached MMR, and 12/18 cases [67%] achieved MMR
at 18 months) than the poor responders (at 12 months, 2/11 cases [18%] reached MMR, and 3/
11 cases [27%] achieved MMR at 18 months) (12m p<0.05; 18m p<0.05; Fig 7A and 7B and
S7A and S7B Fig). The same trend was observed when comparing the BCR-ABL1 transcript
median values at 12 and 18 months (good responders, 0.02% and 0.0%, respectively; the inter-
mediate responders, 0.09% vs. 0.02%, respectively; the poor responders, 0.5% and 0.2%, respec-
tively) (12m p<0.05; 18m p = ns) (Fig 7C and 7D and S7C and S7D Fig).
1 month, the proportion of Ph+CD34+CD38- cells in poor responders (median 56.2%, range 1.1–97) and responders (11.1%, range 0–98.0) C) At
3 months, poor responders had a significantly higher proportion of Ph+CD34+CD38- cells (median 2.8%, range 0–34.9) versus responders
(0.2%, range 0–7.8) (p<0.01). D) Poor responders have a significantly higher percentage of Ph+CD34+CD38+ cells at 1 month (median 86.5%,
range 34.2–94.8) compared to responders (median 32.0%, range 0.9–98.8) (p<0.01). Statistical significance was analyzed with an unpaired two-
tailed t-test, and median values are noted with lines.
doi:10.1371/journal.pone.0171041.g003
Early BCR-ABL1 Transcript Decline in CML
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Poor responders had a significantly worse long-term treatment outcome
Long-term follow-up of the 11 poor responders showed that at 24 months, only 6/11 (54.5%)
patients reached MMR (2 patients who had achieved MMR had switched from dasatinib to
nilotinib) (Table 1). Furthermore, at 36 months, 7/10 patients (70%) had reached MMR (one
had switched from dasatinib to nilotinib). The corresponding numbers for the responders
were 27/31 (87.1%) at both 24 months and 36 months. A chi-square comparison between the
responders and poor responders was significant at 24 months (p = 0.02), but at 36 months no
differences were observed (Table 1).
A detailed characterization of the 11 poor responders revealed that 4 eventually stopped the
treatment drug (imatinib n = 1, dasatinib n = 3), either due to toxicity (n = 3, 1 on imatinib and 2
on dasatinib) or treatment failure (on dasatinib) and switched to other TKIs (1 dasatinib patient
switched to imatinib and 2 to nilotinib; the patient on imatinib discontinued the treatment).
Fig 4. Ph+ in CD34+CD38- and CD34+CD38+ fractions decrease more slowly in the poor responders. The figure presents the proportions of Ph+ cells
in CD34+CD38- (A and B) and CD34+CD38+ (C and D) fractions in responders (A and C) and poor responders (B and D) at the time of dg and during follow-
up (1, 3, and 6 months). Imatinib-treated patients are presented with dashed lines and dasatinib-treated patients with solid lines. Medians in each group are
marked with bold lines.
doi:10.1371/journal.pone.0171041.g004
Early BCR-ABL1 Transcript Decline in CML
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Discussion
Several trials have studied different possibilities to predict the response to TKI therapy at early
time points in chronic phase CML, and most recommend 3 months as the earliest point [7,15–
19]. As TKI therapy in general results in fast responses, we hypothesized that clinically mean-
ingful response prediction would already be possible 1 month after the start of treatment. By
comparing the BCR-ABL1 transcript level at 1 month with the diagnostic value, we identified
poor-responding patients who had no decline in BCR-ABL1 transcript values. Importantly,
regardless of the TKI used (either first- or second-generation drug) a significant proportion of
these patients also failed to achieve optimal response at later time points.
In the current treatment algorithms, BCR-ABL1 transcript level<10% at 3 months is the
first treatment goal and a marker for early response.[7,15–19] However, this classification
does not take into account patient-specific factors, such as initial BCR-ABL1 transcript levels,
which vary considerably between patients.[15,24] Therefore, the individual decline in the
BCR-ABL1 transcript level may be more informative than achieving the 10% landmark per se.
Hanfstein and colleagues have studied the relative changes of BCR-ABL1 transcript levels
within the initial 3 months of therapy and defined good response as an achievement of a half-
log reduction in BCR-ABL1/GUS values. Patients who failed to reach this half-log reduction at
3 months were at higher risk of disease progression.[15] Similarly, Branford et al. have shown
that the early 3-month decline may be a critical prognostic factor when aiming to identify poor
responders.[25] It should also be noted that our key findings remained similar when only
patients in whom GUS has been used as a control gene were analyzed. Thus, the initial individ-
ual decline (or its absence) reflects disease biology, which is not dependent on the control gene
used in the molecular analysis.
As the highest rate of progression to the accelerated and blast phases occurs during the first
year of therapy, it is crucial to define poor-responding patients as early as possible to be able to
modify their treatment in time. Therefore, response evaluation at the 1-month time point may
have great significance for the subsequent outcome. In our patient cohort, we discovered that
one-fifth (21%) of the patients failed to exhibit any decline in BCR-ABL1 transcript levels dur-
ing the first month of TKI therapy. Importantly, we confirmed that this was not due to poor
Fig 5. A third of the poor responders do not achieve a BCR-ABL1 transcript level<10% at 3 months. Using the 3-month BCR-ABL1 transcript
10% classification, 36% of the poor responders had BCR-ABL1 transcripts>10%, whereas 0% of good responders (FC<0.31) and 24% of the
intermediate responders (0.31<FC<1) were categorized into this group (see Fig 1A for classification of patients). Statistical significance was analyzed
with a chi-square test.
doi:10.1371/journal.pone.0171041.g005
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Fig 6. Poor responders have an inferior outcome at 12 and 18 months. A-B) The poor responders achieved MMR more seldom at 12
months (p<0.01) and 18 months (p<0.01) compared to responders. C–D) Poor responders had a higher BCR-ABL1 transcript level at 12
Early BCR-ABL1 Transcript Decline in CML
PLOS ONE | DOI:10.1371/journal.pone.0171041 January 30, 2017 11 / 17
compliance with the therapy, as all patients used full doses of assigned TKIs, according to their
drug accountability logs in the clinical trial records.
All responder patients according to the 1-month FC classification in our study cohort
achieved the 3-month 10% BCR-ABL1 transcript level cut-off value [7,15,16,19], whereas 36%
months compared to the responders (p<0.05), whereas no difference was observed at 18 months. E) According to the ELN 12-month
classification, the poor responders were significantly more often classified as warning and failures than the responders (p<0.05). In panels A, B,
and E, statistical significance was analyzed with a chi-square test. In C and D, an unpaired two-tailed t-test was applied, and median values are
noted with lines.
doi:10.1371/journal.pone.0171041.g006
Fig 7. Poor responders have significantly worse long-term outcomes. The patients were divided into three groups based on the 1-month FC (poor
responders FC>1, intermediate 0.31<FC<1, good FC<0.3; Fig 1A). A–B) The comparison of the three groups showed differences in the MMR rates at 12
(p<0.05) and 18 months (p<0.05). C–D) The BCR-ABL1 transcript value at 12 and 18 months in the three response groups. In A and B, statistical significance
was analyzed with a chi-square test. In C and D, an unpaired two-tailed t-test was applied, and median values are noted with lines.
doi:10.1371/journal.pone.0171041.g007
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of the poor responders failed to achieve this despite their lower initial BCR-ABL1 transcript
value. In addition, according to the ELN recommendations, at the 12-month time point, over
80% of poor responder patients fell into the warning or failure categories, as they had not
reached MMR.[7] Similarly, only 27% of these patients achieved MMR at 18 months. This was
not related to the type of the TKI used, as both imatinib- and dasatinib-treated patients were
represented in equal proportions. No nilotinib-treated patients were in the poor responder
group, but only 5 such patients were evaluated. When MMR rates were evaluated at later time
points (24 and 36 months), the poor responders still had inferior outcomes, although in 36% of
the cases the treatment protocol had been changed. This clearly demonstrates that the poor
responders are more likely to have a long-term poor response.
These results may suggest that the disease biology in the poor responders is different than in
the well-responding patients. Higher initial BCR-ABL1 transcript levels would have been a rea-
sonable explanation for the slow response, but, to our surprise, the poor responder patients
even had a lower median BCR-ABL1 transcript level at dg when compared to the responder
group. Age, total WBC, and blast or basophil counts did not differ between the groups. Inter-
estingly, >50% of poor responder patients had splenomegaly at dg compared to the responder
group, where palpable spleen was only discovered in <15% of the cases. Despite the many
modern advances in diagnostic technology platforms, spleen size still seems to hold great
importance when diagnosing and staging CML. It has been used in all past and current staging
systems, such as in the Sokal, Euro, and EUTOS scores.[13,14,26]
In addition to an enlarged spleen, the poor responders had a higher proportion of Ph+CD34
+CD38- cells in the hematopoietic stem cell compartment. The increased amount of Ph+ stem
cells could partly explain the resistance observed in the poor responders, as it has been previ-
ously shown that quiescent CML stem cells are resistant to TKI therapy.[27–29] In addition,
hemoglobin was observed to be lower in the poor responders at dg. These three factors taken
together (spleen size, hemoglobin and Ph+ stem cells) may better represent the total tumor
load in the body than the initial BCR-ABL1 transcript level, and they therefore may explain the
slower response to therapy. However, as we noticed that half of our poor responders had used
the more potent second-generation TKI (dasatinib), it could also be that the enlarged spleen
does not only imply a higher total tumor burden but also reflects issues with other biological
aspects, such as aberrant signalling pathways that are activated and not well inhibited by the
current TKIs. Interestingly, in the poor responder group, the disappearance of leukemic Ph+
CD34+CD38+ cells was especially slow when compared to the responder group. As Ph+CD34+
CD38+ cells are a rapidly dividing cell population, it could be that the initial increase in the
BCR-ABL1 transcript levels in the poor responder group mirrors the inefficiency of the TKI ther-
apy used to inhibit this cell population. Of note, the poor responders had been treated signifi-
cantly more often with hydroxyurea than the responding patients. Despite the hydroxyurea,
these patients still responded poorly, most likely due to a higher tumor burden that was repre-
sented, for example, in the form of splenomegaly and increased leukemic stem cell burden. It
has been previously observed that hydroxyurea can induce cytogenetic responses in some
patients,[30,31] and therefore its use does not explain slower treatment responses in our patients.
Table 1. Differences in the MMR rates at 24 and 36 months between responder and poor responder groups.
24 months molecular response 36 months molecular response
no MMR MMR Total no MMR MMR Total
Responders (percent) 4 (12.9%) 27 (87.1%) 31 (100%) 4 (12.9%) 27 (87.1%) 31 (100%)
Poor responders (percent) 5 (45.5%) 6 (54.5%) 11(100%) 3 (30%) 7 (70%) 10 (100%)
pchi-square 0.024 ns
doi:10.1371/journal.pone.0171041.t001
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In conclusion, our results suggest that the early in vivo response to TKI therapy after 1
month appears predictive for later treatment results. Patients who do not show any decline in
the BCR-ABL1 transcript levels during the first month of TKI therapy (i.e., poor responders)
may have a different disease biology or significantly higher tumor burden. Thus, early response
evaluation is warranted in prospective clinical trials.
Supporting Information
S1 Fig. Comparison of GUS and ABL control genes. A) The initial BCR-ABL1 transcript
value at dg. Patients with the GUS and ABL control genes are highlighted with different sym-
bols. B) The patients in whom the ABL gene was used as the reference gene at dg had a signifi-
cantly higher BCR-ABL1 transcript value than the patients whose reference gene was GUS
(p<0.05). C) If only cases in which GUS was used as a reference gene were considered, the ini-
tial BCR-ABL1 transcript value was still lower in the poor responder group (p<0.05). Statistical
significance was analyzed with an unpaired two-tailed t-test, and median values are noted with
lines. D) Division of the patient groups based on the fold-change values (only patients with
GUS control gene are presented). The 1-month BCR-ABL1 transcript value was divided by the
BCR-ABL1 transcript value at dg, and poor responders were identified as patients with FC>1
(no decrease in BCR-ABL1 transcript value after 1 month). The patients with an FC lower than
1 were defined as responders. Furthermore, we used the median FC (0.22) of the responders to
divide these patients into an intermediate response group (0.22<FC<1) and good response
group (FC<0.22).
(TIF)
S2 Fig. The poor responders have enlarged spleen at dg (shown are patients with GUS as a
control gene). A) The proportion of Ph+ cells in the CD34+CD38- and CD34+CD38+ cell
compartments was analyzed by sorting and FISH. The poor responders tend to have a higher
proportion of Ph+CD34+CD38- cells at dg when compared to the responder group (p = 0.08).
B) No difference was observed in the proportion of Ph+CD34+CD38+ cells at dg. C) Difference
in the size of the spleen (measured as the palpable part under the costal margin) between the
poor responder and responder groups (p<0.001). D) Proportion of patients with enlarged spleen
(pchi square = 0.001). E) Hemoglobin levels in poor responders and responders (p<0.001). Statis-
tical significance was analyzed with an unpaired two-tailed t-test, and median values are noted
with lines. In panel D, a chi-square test was used.
(TIF)
S3 Fig. The Ph+CD34+CD38- cells are more slowly eradicated in poor responders (patients
with GUS as a control gene). A) At 1 month, the BCR-ABL1 transcript level was significantly
higher in poor responders (median 40.2%, range 11–98.7) compared to responders (median
8.1%, range 0.99–58.7), (p<0.0001). B) At 1 month, the proportion of Ph+CD34+CD38- cells
in poor responders (median 56.2%, range 1.1–97) and responders (14%, range 0–98.0). C) At
3 months, poor responders had a significantly higher proportion of Ph+CD34+CD38- cells
(median 2.8%, range 0–34.9) versus responders (0.2%, range 0–2), (p<0.05). D) Poor respond-
ers have a significantly higher percentage of Ph+CD34+CD38+ cells at 1 month, median 86.5%
(range 34.2–94.8) compared to responders (median 26.9%, range 3.1–98.8) (p<0.001). Statisti-
cal significance was analyzed with an unpaired two-tailed t-test, and median values are noted
with lines.
(TIF)
S4 Fig. Ph+ in CD34+CD38- and CD34+CD38+ fractions decrease more slowly in the poor
responders (patients with GUS as a control gene). The figure presents the proportions of
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Ph+ cells in CD34+CD38- (A and B) and CD34+CD38+ (C and D) fractions in responders (A
and C) and poor responders (B and D) at the time of dg and during follow-up (1, 3, and 6
months). Imatinib-treated patients are presented with yellow lines and dasatinib-treated
patients with blue lines. Medians in each group are marked with green lines.
(TIF)
S5 Fig. A third of the poor responders do not achieve BCR-ABL1 transcript level<10% at 3
months (patients with GUS as a control gene). Using the 3-month BCR-ABL1 transcript level
10% classification, 36% of the poor responders had BCR-ABL1 transcript level>10%, whereas
0% of good responders (FC<0.22) and 24% of the intermediate responders (0.22<FC<1) were
categorized into this group. Statistical significance was analyzed with a chi-square test.
(TIF)
S6 Fig. Poor responders have inferior outcomes at 12 and 18 months (shown are patients
with GUS as a control gene). A-B) The poor responders achieved MMR more seldom at 12
months (p<0.01) and 18 months (p<0.05) compared to responders. C-D) Poor responders had
a higher BCR-ABL1 transcript level at 12 months compared to the responders (p<0.05),
whereas no difference was observed at 18 months. E) According to the ELN 12-month classifi-
cation, the poor responders were significantly more often classified as warning and failures
than the responders (p<0.05). In A, B, and E, statistical significance was analyzed with a chi-
square test. In C and D, an unpaired two-tailed t-test was applied, and median values are noted
with lines.
(TIF)
S7 Fig. Poor responders have significantly worse long-term outcomes (shown are patients
with GUS as a control gene). The patients were divided into three groups based on the
1-month FC (poor responders FC>1, intermediate 0.22<FC<1, good FC<0.22; S1D Fig). A–B)
The comparison of the three groups showed differences in the MMR rates at 12 (p<0.05) and
18 months (p = 0.05) C–D) The BCR-ABL1 transcript values at 12 and 18 months in the three
response groups. In A and B, statistical significance was analyzed with a chi-square test. In C
and D, an unpaired two-tailed t-test was applied, and median values are noted with lines.
(TIF)
S1 Table. A. Characteristics of the poor responder patients based on the 1 month/dg
BCR-ABL1 transcript fold-change ratio. B. Characteristics of the responders based on the 1
month/dg BCR-ABL1 transcript fold-change ratio (FC<1).
(DOCX)
S2 Table. Differences between responders (FC<1) and poor responders (FC>1) in bone
marrow (BM) and peripheral blood differential counts.
(DOCX)
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